Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
Clinical trial NCT03737981 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03737981
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-31
- Primary completion
- 2025-01-17
- Enrollment
- 465
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.